News

A group of UK professors and scientists efforts to identify possible direct therapeutic approaches to treat COVID-19 was published in the Perspectives section of the most recent issue of Science, a journal of the American Association for the Advancement of Science (AAAS).

UK researchers have launched antibody testing that will help to understand what immunity to COVID-19 really means. The research is part of UK’s CURE Alliance team, which is uniting UK researchers across disciplines in the fight against the novel coronavirus.

“We are pleased to be able to offer this clinical trial to patients with COVID-19 in Kentucky. While there is no standard treatment for COVID-19, this trial gives us the ability to test multiple therapies rapidly in order to identify the most promising agents.”

The Kentucky Conference on Health Communication (KCHC), which was supposed to be held April 2-4, 2020, at the Hyatt Regency in Lexington, made the swift change to a virtual conference amid the COVID-19 pandemic.

According to the report, confirmed COVID-19 cases in the Commonwealth would have reached a staggering 45,000 by April 25 without any state-imposed measures. For comparison, the current total of confirmed COVID-19 cases is fewer than 4,000.

The UK CURE Alliance, in collaboration with the UK Center for Clinical and Translational Science, has issued RFAs for COVID-19 funding in three categories: health, materials and methods and social sciences. Full-time UK faculty in all title series are eligible to apply.

Sutton is the first UK researcher to receive funding for COVID-19 related work as part of the NSF's Rapid Response Research (RAPID) grant program, which enables the agency to quickly process and support research that addresses an urgent need.

John Thelin is a leading authority on the history of American higher education. Today, he answers some of our questions, bringing historical knowledge to contemporary discussions around COVID-19’s impact on higher education.

Across the country, a lot of health care-related research has been paused as people are asked to stay home and maintain social distancing. However, there’s some good news: many clinical trials are still underway.

In response to the COVID-19 pandemic, UK's Center for Clinical and Translational Science (CCTS) has created a new biospecimen bank to support research on the novel virus. Logistical support for the biobank is led by the UK Markey Cancer Center.